[HTML][HTML] Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
M Benvenuto, S Ciuffa, C Focaccetti, D Sbardella… - Scientific reports, 2021 - nature.com
Head and neck cancer (HNC) has frequently an aggressive course for the development of
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
M Benvenuto, S Ciuffa, C Focaccetti… - Scientific …, 2021 - ui.adsabs.harvard.edu
Head and neck cancer (HNC) has frequently an aggressive course for the development of
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
M Benvenuto, S Ciuffa, C Focaccetti… - SCIENTIFIC …, 2021 - art.torvergata.it
Head and neck cancer (HNC) has frequently an aggressive course for the development of
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells.
M Benvenuto, S Ciuffa, C Focaccetti… - Scientific …, 2021 - search.ebscohost.com
Head and neck cancer (HNC) has frequently an aggressive course for the development of
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
M Benvenuto, S Ciuffa, C Focaccetti… - SCIENTIFIC …, 2021 - iris.uniroma1.it
Head and neck cancer (HNC) has frequently an aggressive course for the development of
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
[PDF][PDF] Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor‑infiltrating immune cells
M Benvenuto, S Ciuffa, C Focaccetti, D Sbardella… - Scientific Reports, 2021 - core.ac.uk
Results Inhibition of tongue (SCC‑15, CAL‑27), pharynx (FaDu), and salivary gland (A‑253,
SALTO‑5) cancer cells survival and death by Bortezomib. The survival of tongue (SCC-15 …
SALTO‑5) cancer cells survival and death by Bortezomib. The survival of tongue (SCC-15 …
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
M Benvenuto, S Ciuffa, C Focaccetti… - SCIENTIFIC …, 2021 - iris.uniroma5.it
Head and neck cancer (HNC) has frequently an aggressive course for the development of
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells.
M Benvenuto, S Ciuffa, C Focaccetti, D Sbardella… - Scientific …, 2021 - europepmc.org
Head and neck cancer (HNC) has frequently an aggressive course for the development of
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
[HTML][HTML] Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
M Benvenuto, S Ciuffa, C Focaccetti, D Sbardella… - Scientific …, 2021 - ncbi.nlm.nih.gov
Head and neck cancer (HNC) has frequently an aggressive course for the development of
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
M Benvenuto, S Ciuffa, C Focaccetti… - Scientific …, 2021 - pubmed.ncbi.nlm.nih.gov
Head and neck cancer (HNC) has frequently an aggressive course for the development of
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …
resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being …